VERVE THERAPEUTICS INC (VERV)
Institutional ownership reported to the SEC as of Q4 2025, across 19 quarters.
1
Reporting holders
$344
Reported value
0.0%
Held as options
-4
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| DekaBank Deutsche Girozentrale | $344 | 24,000 | 0.00% | 14q | HELD |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q4 2025 | 1 | $344 | 24,000 | 0 | 0 | 0 | 0.0% |
| Q3 2025 | 5 | $1.0M | 91,958 | 0 | 1 | 1 | 0.0% |
| Q2 2025 | 163 | $858.3M | 72,640,239 | 43 | 46 | 61 | 5.0% |
| Q1 2025 | 176 | $356.9M | 77,913,090 | 39 | 43 | 53 | 0.4% |
| Q4 2024 | 152 | $430.0M | 76,127,260 | 11 | 56 | 42 | 0.4% |
| Q3 2024 | 155 | $359.0M | 74,101,308 | 27 | 56 | 37 | 0.4% |
| Q2 2024 | 151 | $356.8M | 72,975,569 | 30 | 58 | 41 | 0.4% |
| Q1 2024 | 144 | $1.1B | 79,834,582 | 24 | 62 | 33 | 0.4% |
| Q4 2023 | 139 | $1.0B | 73,303,090 | 30 | 61 | 18 | 0.7% |
| Q3 2023 | 118 | $817.4M | 60,757,027 | 27 | 47 | 21 | 1.5% |
| Q2 2023 | 104 | $1.1B | 58,887,022 | 13 | 40 | 31 | 0.2% |
| Q1 2023 | 101 | $960.2M | 66,473,780 | 18 | 34 | 24 | 0.3% |
| Q4 2022 | 96 | $1.1B | 56,798,535 | 22 | 37 | 19 | 0.9% |
| Q3 2022 | 127 | $2.1B | 60,702,117 | 45 | 55 | 16 | 1.1% |
| Q2 2022 | 98 | $699.9M | 45,570,487 | 25 | 30 | 20 | 0.6% |
| Q1 2022 | 93 | $1.1B | 46,647,422 | 20 | 39 | 22 | 0.1% |
| Q4 2021 | 92 | $1.7B | 45,217,916 | 30 | 31 | 18 | 0.1% |
| Q3 2021 | 73 | $1.8B | 38,717,770 | 33 | 16 | 13 | 0.0% |
| Q2 2021 | 69 | $2.3B | 37,677,848 | 69 | 0 | 0 | 0.0% |